Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Clinically speaking, Roche/Genentech’s injectable Lucentis (ranibizumab) looks well-positioned for a role in diabetic macular edema after the full release of Phase III trial data.
Advertisement

Related Content

Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

Topics

Advertisement
UsernamePublicRestriction

Register

PS004787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel